Search clinical trials for: Iptacopan

Total 19 results

Novartis Pharmaceuticals

Recruiting

Long-term Efficacy, Safety and Tolerability of LNP023 in C3G

C3 Glomerulopathy

Spain, France, Germany, Switzerland, United States, Japan, Turkey, China, United Kingdom, Italy, Argentina, Brazil, Greece, Israel, Netherlands
Novartis Pharmaceuticals

Completed

Pharmacokinetic (PK) and Safety Study of Iptacopan (LNP023) in Participants With Mild, Moderate, and Severe Hepatic Impairment Compared to Matched Control Healthy Participants With Normal Hepatic Function.

Hepatic Impairment

United States
Novartis Pharmaceuticals

Recruiting

Study of Efficacy and Safety of LNP023 in Participants With Active Lupus Nephritis Class III-IV, +/- V

Lupus Nephritis

France, Spain, Israel, Turkey, United States, Germany, India, Hungary, Malaysia, Portugal, Brazil, China, Puerto Rico, Hong Kong, Mexico, Singapore
Novartis Pharmaceuticals

Active, not recruiting

Basket Study to Assess Efficacy, Safety and PK of Iptacopan (LNP023) in Autoimmune Benign Hematological Disorders

Immune Thrombocytopenia (ITP) | Cold Agglutinin Disease (CAD)

United States, Spain, Germany, Korea, Republic of, United Kingdom, Italy
Novartis Pharmaceuticals

Recruiting

A Masked, Placebo-controlled Study to Assess Iptacopan in Age-related Macular Degeneration

Age-Related Macular Degeneration

China, United States, Puerto Rico, United Kingdom
Novartis Pharmaceuticals

Completed

Study of Efficacy and Safety of Twice Daily Oral Iptacopan (LNP023) in Adult PNH Patients Who Are Naive to Complement Inhibitor Therapy (APPOINT-PNH)

Paroxysmal Nocturnal Hemoglobinuria (PNH)

China, Germany, Singapore, Korea, Republic of, Italy, United Kingdom, Malaysia, France
Novartis Pharmaceuticals

Recruiting

Efficacy and Safety of Switching From Anti-C5 Antibody Treatment to Iptacopan Treatment in Study Participants With Atypical Hemolytic Uremic Syndrome (aHUS)

Atypical Hemolytic Uremic Syndrome

Japan, Turkey
Novartis Pharmaceuticals

Recruiting

Single Arm, Open Label Trial With Iptacopan Treatment for 24 Weeks, in Patients on Stable Regimen of Anti-C5 Who Switch to Iptacopan. (APPULSE)

Paroxysmal Nocturnal Hemoglobinuria

France, Spain, Italy, Turkey, Germany, United States, Korea, Republic of, United Kingdom
Novartis Pharmaceuticals

Recruiting

Study of Efficacy and Safety of Iptacopan in Patients With C3 Glomerulopathy. (APPEAR-C3G)

C3G

Spain, France, Switzerland, Germany, Greece, Turkey, Canada, India, United States, Czechia, Japan, Argentina, Brazil, Italy, Israel, United Kingdom, China, Belgium, Netherlands
Novartis Pharmaceuticals

Active, not recruiting

Study of Efficacy and Safety of LNP023 in Primary IgA Nephropathy Patients (APPLAUSE-IgAN)

IgA Nephropathy

United States, Taiwan, Czechia, Germany, Hungary, India, Turkey, Belgium, Netherlands, Singapore, Australia, Canada, Italy, Korea, Republic of, Spain, Thailand, Denmark, Slovenia, United Kingdom, Argentina, Brazil, Israel, Japan, France, Swed... and more
Novartis Pharmaceuticals

Recruiting

A Rollover Extension Program (REP) to Evaluate the Long-term Safety and Tolerability of Open Label Iptacopan/LNP023 in Participants With Primary IgA Nephropathy

Primary IgA Nephropathy

Japan, Korea, Republic of, United States, Denmark, France, Taiwan, Belgium, Israel, Thailand, Germany, India, Czechia, Malaysia, Argentina, Singapore, China, Australia, Norway, Turkey, United Kingdom, Brazil, Hong Kong, Netherlands, C... and more
Novartis Pharmaceuticals

Recruiting

Study of Efficacy and Safety of Iptacopan in Participants With IC-MPGN (APPARENT)

IC-MPGN

France, Germany, Spain, Switzerland, Japan, United Kingdom, Israel, Brazil, Turkey, Italy, United States, Czechia, Poland
Novartis Pharmaceuticals

Recruiting

Efficacy and Safety of Iptacopan (LNP023) in Adult Patients With Atypical Hemolytic Uremic Syndrome Naive to Complement Inhibitor Therapy (APPELHUS)

Atypical Hemolytic Uremic Syndrome

China, Korea, Republic of, Austria, Taiwan, Greece, United States, Czechia, Japan, Brazil, United Kingdom, India, Slovenia, Slovakia
Novartis Pharmaceuticals

Available

Managed Access Programs for LNP023, Iptacopan

Paroxysmal Nocturnal Hemoglobinuria (PNH) | C3 Glomerulopathy (C3G)
Novartis Pharmaceuticals

Completed

Study of Safety, Efficacy, Tolerability, Pharmacokinetics and Pharmacodynamics of LNP023 in in Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH)

Paroxysmal Nocturnal Hemoglobinuria (PNH) With Signs of Active Hemolysis

Italy, Germany, France
Novartis Pharmaceuticals

Not yet recruiting

Evaluate Long-term Safety, Tolerability and Efficacy of Iptacopan in Study Participants With aHUS

Atypical Hemolytic Uremic Syndrome
Novartis Pharmaceuticals

Recruiting

Long-term Safety and Tolerability of Iptacopan in Patients With Paroxysmal Nocturnal Hemoglobinuria

Paroxysmal Nocturnal Hemoglobinuria

United States, Korea, Republic of, Singapore, Germany, Taiwan, Italy, Turkey, France, Malaysia, Lithuania, Netherlands, United Kingdom, Japan, Czechia, Spain, China, Brazil
Novartis Pharmaceuticals

Completed

Efficacy, Safety, Pharmacokinetics and Pharmacodynamics Study, Assessing Multiple LNP023 Doses in Adult Patients With Paroxysmal Nocturnal Hemoglobinuria

Paroxysmal Nocturnal Hemoglobinuria

Taiwan, Singapore, Korea, Republic of, Malaysia
Novartis Pharmaceuticals

Completed

Study of Efficacy and Safety of Twice Daily Oral LNP023 in Adult PNH Patients With Residual Anemia Despite Anti-C5 Antibody Treatment (APPLY-PNH)

Paroxysmal Nocturnal Hemoglobinuria (PNH)

Italy, Japan, Taiwan, Germany, France, United Kingdom, Spain, Korea, Republic of, Czechia, Brazil, Netherlands, United States

Search clinical trials for: Iptacopan

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Türkiye

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations